for example, xarelto, one of the drugs on the list, cost three times more in the us than in canada.otiating drug prices could save medicare. an estimated $98.5 billion over a decade. as for how much seniors will save, the white house says that's yet to be determined. >> we don't know what the negotiated price will be. this is a subject in negotiation, so we can't tell you the specific amount that people will save. but there will be savings to people both paying out of pocket and also to the medicare program itself. >> critics say this plan will hurt innovation in the pharmaceutical industry and could lead to price controls. seniors won't see any savings until 2026, assuming the plan clears legal hurdles. and coming up, more coverage from florida as hurricane idalia approaches. >> but first, the new legal battle over schools notifying parents if their children come out as transgender. and a shooting inside a major league ballpark. >> how a woman reportedly snuck the gun through security they just know their way around a good deal. that's why, we hired them all. at marshalls, our buye

xarelto and eliquis to prevent prevent strokes and blood clots. jardiance and januvia, which treat type-2 diabetes. farxiga, for people with chronic kidney disease. entresto to stave off heart failure. enbrel for about fly dis. imbruvica, for blood cancers. stelara, for crohn's disease, and fiasp and novolog, both insulin products, for diabetics. as many as 9 million seniors take at least one of those drugs on the list. some paying up to $6,500 out of pocket each year. teddie brewer, a retired school principal from las vegas, relies on the drug eliquis, to treat her irregular heartbeat. >> when i go into the pharmacy and i say, i'm here to pick up my eliquis, the pharmacist always say, you know, it's very expense. and i say, i know, but it's that, or risk having a heart attack. so, i guess i'll just have to pay it. >> reporter: americans pay more for prescription drugs than any country in the world. xarelto, for example, that drug for blood clots, costs three times more in the u.s. than it does in canada. now negotiating drug prices directly with

xarelto, the blood thinner mentioned earlier, is likely on there and a couple more will come. host: take your time. we have agnes on southeastern massachusetts, you're on with julie. guest: my question is, how do we get all the financial for-profit middlemen out of health care, so not just the pv -- pbm's, but the for-profit venture capital firms that are buying up hospitals -- it's everywhere. guest: yes. we have a big project on private equity and health care. there are differences between parts of the health-care system that are intended to make a profit -- for-profit hospitals, for-profit pieces of the health care system, and the drug industry is a for-profit piece of the health care system. but there are private equity companies coming in not so much because they want to deliver health care, but because there is a lot of money and health care and they would like to share in some of that money. there are issues going on in private equity, buying up places in pennsylvania and they closed it down because the real estate was worth more than the hospital. that is a separate is

sheldon armas takes xarelto, one of the medications on the list. he says that skyrocketing drug costs hurt not only seniors but taxpayers, too. >> it should have been negotiated way down so the american public doesn't have to pay the balance. >> reporter: the negotiated prices are scheduled to take effect in 2026. >> the biden administration says this is just the first wave of negotiated prices. they plan to add up to 60 drugs to that list in the future. >>> if you use an apple iphone, whatever model you have might soon feel obsolete! >> apple getting ready to unveil new products for the upcoming year. tech experts believe that apple will likely reveal their new iphone 15 and iphone 15 pro! the new devices are expected to feature a better camera, faster charging and a longer battery life. there may also be more color choices for customers. >> i will keep my iphone 6! the company also revealed new versions of the apple watch and apple watch ultra. the event will happen in two weeks on september 12th. >>> still ahead, csu is under the microscope for

list for price cut negotiations, along with januvia, fiasp, and novolog for diabetes eliquis and xarelto, both blood thinners. enbrel for arthritis farxiga for diabetes and kidney disease. entresto for heart failure and stelara for psoriasis and crohn's disease >> today is the start of a new deal for patients, where big pharma doesn't just get a blank check. >> reporter: in 2003, the republican congress banned medicare from negotiating lower drug prices. the new law empowers medicare to do just that -- negotiate. if drug companies don't participate, they face tax penalties. the pharma industry is suing to block the law, claiming it will mean less money for new drugs, and politics should not deck state which treatments and cures are worth developing, and who should get access to them but after capping insulin at $35, polls show broad support for more price caps. >> this is fundamentally about putting prescriptions back in the reach of people, by making them more affordable. >> reporter: pending legal challenges, the new prices on these ten meds should take effect in 2026, then more drug p

xarelto, the blood thinners that was mentioned earlier, is likely on their. probably a couple of the company trend we tremor we had about 20 more minutes. we have agnes in southeastern massachusetts next on with julie rovner wow my question is, how do we get all the financial profit movement out of healthcare? so not just the pbms but all those entities, all those venture capital firm that are buying up hospitals, physician practices and such peer it's just everywhere. >> guest: yes. we have kf f health we have private equity and healthcare. differences between parts of health care system that are intended to make a profit, they are a for-profit hospitals, lots of for-profit pieces of health care system. the drug industry is a for-profit piece of healthcare system but then there are private equity companies coming in not so much because they want to deliver healthcare but because there's a lot of money and they would like to share in some of that money. there are definitely issues going on in private equity by up for instance, in pennsylvania private equity b

ten of the most widely used drugs, including eliquis jardiance and xarelto, will be targeted for price reduction within the medicare program. most users are seniors. those over 65. so so this is a very good thing. along with the cap for medicare of the $2,000 cap, the $2,000 cap is the most anyone using medicare will pay out of pocket. the drugs listed for price cuts include drugs that treat diabetes, blood clots, psoriasis and blood cancers. the center for elders independence in oakland says they have a special program that provides medication to seniors free of charge. but we have to pay for the medicines and we have to live within a budget. so it's very important for everybody that wants quality health care to have our medications at a reasonable price. last year, patients on medicare paid $3.4 billion of out-of-pocket costs for drugs. medicare also paid more than $50 billion for prescription drugs from june 2022 until may 31st of this year. doctor middleberg says negotiating fair prices for prescription drugs will help millions of americans. but there will be some resistance from d

. >> reporter: this is the list of drugs at play -- xarelto and eliquis to prevent strokes and blood clots. jardiance and januvia, which treat type-2 diabetes. farxiga, for people with chronic kidney disease. entresto to stave off heart failure. enbrel for arthritis. imbruvica for blood cancers. stelara for crohn's disease. and fiasp and novolog, both insulin products for diabetics. as many as 9 million seniors take at least one of the drugs on the list. some paying up to $6,500 out of pocket each year. teddie brewer, a retired school principal from las vegas, relies on the drug eliquis to treat her irregular heartbeat. >> the pharmacist will always say, you know, this is very expensive, and i said, i know, but it's either that, or risk having a heart attack, so, i guess i'll just have to pay it. >> reporter: the exact amount seniors will save is still unknown, but tonight, the white house making it clear, they will save. so, how much of those savings will go directly to seniors on medicare? >> we don't know what the negotiated price will be. this is a subject to negotiation. so, we

ten of the most widely used drugs, including eliquis jardiance and xarelto, will be targeted for price reduction within the medicare program. most users are seniors. those over 65. so so this is a very good thing. along with the cap for medicare of, you know, the $2,000 cap, the $2,000 cap is the most anyone using medicare will pay out of pocket . the drugs listed for price cuts include drugs that treat diabetes, blood clots, psoriasis and blood cancers. the center for elders independence in oakland says they have a special program that provides medication to seniors free of charge. but we have to pay for the medicines and we have to live within a budget. so it's very important for everybody that wants quality health care to have our medications at a reasonable price. last year, patients on medicare paid $3.4 billion of out-of-pocket costs for drugs. medicare also paid more than $50 billion for prescription drugs from june 2022 until may 31st of this year. a doctor mittelberger says negotiate dating fair prices for prescription drugs will help millions of americans , but there will be

farxiga, eliquis, jardiance, xarelto, januvia, stelara, novolog. spoke with somebody in the industry who represents the people who invest millions in pharmaceuticals. he says drugmakers are concerned smaller profits will leave them with less money for research. >> which may mean that pharmaceutical companies choose not to be in this market or they may choose not to develop a drug for the american market, and we've already seen some companies make some tough decisions because the economics under this new system make no sense. and so we face the inevitable choice of fewer medicines available in order to achieve some cost savings. >>> a new study from a research firm take a look at housing and rental markets in various american cities and asked the question, if you're renting, what kind of house could you get for the same payment you're making every month? they found in some cities it made more sense to buy. in las vegas, the average $1,500 would pay for a mortgage on an 1,100 square foot home. it's a small house, but a house. the average rent in san

xarelto, jar decency, they will now be subject to that, how will these negotiations impact you at cencora>> cencora, i nearly said -- [laughter] liz: i know, i almost did too. >> we try to to follow the prescription dollar. so we have some of the best, most prolific customers in health care particularly in the united states and in europe. we serve independent pharmacies. so we want to service the prescription dollar. and, you know, we believe that the prescription dollars will begin -- continue to flow -- liz: no matter if there's negotiation. >> absolutely. because prescriptions are the most efficient form of health care, and we represent so much of the sector, you know, whether it's the largest health systems or it's community pardon me sayses or it's large chains -- pharmacies or large chains like walgreens on benefit management companies like express scripps cigna, so we are, you know, our role is very important in the infrastructure. hence, the name cencora, because we want to believe we are central to the health care economies. that's why we just more and more love this name. a good

ten of the most widely used drugs, including eliquis, jardiance and xarelto, will be targeted for price reduction within the medicare program. most users are seniors. those over 65. so this is a very good thing. along with the cap for medicare of the $2,000 cap, the $2,000 cap is the most anyone using medicare will pay out of pocket. the drugs listed for price cuts include drugs that treat diabetes, blood clots, psoriasis and blood cancers. the center for elders independence in oakland says they have a special program that provides medication to seniors free of charge. but we have to pay for the medicines and we have to live within a budget. so it's very important for everybody that wants quality health care to have our medications at a reasonable price. last year, patients on medicare paid $3.4 billion of out-of-pocket costs for drugs. medicare also paid more than $50 billion for prescription drugs from june 2020 to until may 31st of this year. doctor mittelberger says negotiating fair prices for prescription drugs will help millions of americans. but there will be some resistance from

popular blood thinners like eliquis and xarelto are on the list, as well as diabetes medications likest year, just these 10 drugs cost medicare recipients $3.4 billion out-of-pocket and cost the medicare program $50 billion. president biden celebrated the milestone at the white house today. pres. biden: today is the start of a new deal for patients, where big pharma doesn't just get a blank check at your expense and expense of the american people. on my watch, healthcare should be right, not a privilege in this country. stephanie: pharmaceutical companies, which have mounted legal challenges to the law, have to negotiate or face heavy tax penalties. the new prices will only take effect in 2026. stacie dusetzina has been watching all of this closely. she's a professor of health policy and cancer research at vanderbilt university school of medicine. stacie, explain why his announcement is a big deal, and how will it impact of those who take those specific 10 medications? , for example, so -- prof. dusetzina: so, it is a really big deal, because when me medicare part d was first enacted,

xarelto, the blood thinner mentioned earlier, is likely on there and a couple more will come. take your time. we have agnes on southeastern massachusetts, you're on with julie. guest: my question is, how do we get all the financial for-profit middlemen out of health care, so not just the pv -- pbm's, but the for-profit venture capital firms that are buying up hospitals -- it's everywhere. guest: yes. we have a big project on private equity and health care. there are differences between parts of the health-care system that are intended to make a profit -- for-profit hospitals, for-profit pieces of the health care system, and the drug industry is a for-profit piece of the health care system. but there are private equity companies coming in not so much because they want to deliver health care, but because there is a lot of money and health care and they would like to share in some of that money. there are issues going on in private equity, buying up places in pennsylvania and they closed it down because the real estate was worth more than the hospital. that is a separate issue go

xarelto on here. diabetes drugs. oncology drugs. that sounds roughly right.e all tried to run through what the top ten drugs might be. what companies are impacted. when i looked at it, bristol, merck, pfizer, abbvie are the top impacted. >> what with's the rational? >> this will kick in in 2026. we have a couple of years before it is implemented. we are seeing pharma work around it. pfizer has done six acquisitions or attempting to do the sixth acquisition in less than two years with seagen. amgen is trying to lock up horizon. a lot of mm&a is taking place sdpplace. >> would you make a decision to hold on to them or buy them? >> we have been in a holding pattern waiting for the top ten since the i.r.a. came out. i feel if the stock dips another 3% to 5% on the headline, i would buy for a trade. i'm not sure much more. >> jared, thanks. it's early. you had to set an alarm for today. >> you bet. sure. >> talk to you later. >>> when we come back, from prescription drugs to the cost of being a caregiver. sharon epperson has a report on the financial and emotional